Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma

Sorigue, Marc; Bishton, Mark; Domingo-Domenech, Eva; McMillan, Andrew; Prusila, Roosa; García, Olga; Kuusisto, Milla; Condom, Maria; Tapia, Gustavo; Ribera, Josep-María; Kuittinen, Outi; Fox, Christopher P; Sancho, Juan-Manuel

Abstract

Short responses to immunochemotherapy predict for an inferior OS in follicular lymphoma. We set out to determine whether this is also the case in marginal zone lymphoma. A group of 139 marginal zone lymphoma (MZL) patients treated with front-line immuno- or immunochemotherapy (I/ICT) were categorized into I/ICT-refractory (non-response or relapse/progression within six months of treatment response assessment) or I/ICT-sensitive. Twenty-three patients (17%) were refractory. Refractory patients had inferior OS (4-yr probabilities of 57% vs. 83%, p = .0003) as did those with beta2-microglobulin (B2M)>3 mg/L (4-yr probabilities of 80% vs. 100%, p = .0029). On multivariable analysis they both showed a borderline significant correlation with OS (p = .06 and .07, respectively). B2M > 3 mg/L was also an adverse prognostic factor for progression-free survival in both univariable (4-yr probability of 61% vs. 83%, p = .02) and multivariable analysis (HR 2.9, p = .02). In conclusion, B2M and refractoriness to I/ICT may identify patients with MZL at higher risk of inferior survival.

Citation

Sorigue, M., Bishton, M., Domingo-Domenech, E., McMillan, A., Prusila, R., García, O., …Sancho, J. (2019). Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma. Leukemia & Lymphoma, 60(10), 2524-2531. https://doi.org/10.1080/10428194.2019.1594212

• Journal Article Type: Article
• Acceptance Date: Mar 9, 2019
• Online Publication Date: Apr 3, 2019
• Publication Date: Aug 24, 2019
• Deposit Date: Aug 1, 2023
• Journal: Leukemia & Lymphoma
• Print ISSN: 1042-8194
• Electronic ISSN: 1029-2403
• Publisher: Taylor and Francis
• Peer Reviewed: Peer Reviewed
• Volume: 60
• Issue: 10
• Pages: 2524-2531
• DOI: https://doi.org/10.1080/10428194.2019.1594212
• Keywords: Marginal zone lymphoma, beta-2 microglobulin, bone marrow involvement, immunochemotherapy, refractoriness,transformation, prognosis, survival
• Public URL: https://nottingham-repository.worktribe.com/output/23550591
• Publisher URL: https://www.tandfonline.com/doi/full/10.1080/10428194.2019.1594212
• PMID: 30942640